top of page
4 Companies with FDA Approval Decisions Expected Before the End of January 🗓️
We’re always excited to find bio/pharma companies nearing their therapeutic product launch! These 4 companies have FDA final approval decision (PDUFA) dates before the end of January: Atara Biotherapeutics (NASDAQ: ATRA ) Drug/Therapy: Tab-cel (tabelecleucel) Allogeneic T-cell immunotherapy Indication: Post-Transplant Lymphoproliferative Disease (PTLD) PDUFA date: January 15, 2025 BLA with priority review Biogen (NASDAQ: BIIB ) Drug/Therapy: Leqembi (Lecanemab) IV Maintenance
Jan 5, 2025
4 Companies with FDA Approval Decisions Expected Before the End of January 🗓️
We’re always excited to find bio/pharma companies nearing their therapeutic product launch!
Jan 5, 2025
BIIB & SAGE: Zuranolone
Big PDUFA from a big collaboration: BIIB & SAGE PDUFA - 8/5/23 - Zuranolone in MDD & PPD Collaboration since 2020… BIIB invested $1.5B in...
Aug 7, 2023
Finally, Therapeutics that slow Alzheimer’s...
But, which is the best?
Jul 16, 2023
New Era In Alzheimer's Treatments Brings Opportunities for Biopharma Investors
ALHEIMER’S BREAKTHROUGH
Jun 19, 2023
HAS THE MARKET BEEN TOO HARSH ON $ABOS?
HAS THE MARKET BEEN TOO HARSH ON $ABOS?
Apr 8, 2023
Apr 3, 2023
Mar 9, 2023
How does Lecanemab compare to other Alzheimer's assets?
Summary: Biogen and Eisai's asset Lecanemab has a PDUFA date set for Friday 1/6/23 Lecanemab targets and effectively reduces beta-amyloid...
Jan 4, 2023
Jan 4, 2023
June/July 2022 - Biotech Stocks Are Back?
Biotech stocks are down ~40% since Jan 1, 2021, underperforming the broader markets The democratic white house and Congress since January...
Jul 11, 2022
Q1 2022 RA Capital Hedge Fund Update
At BPIQ we have started to track quarterly 13F filings for some of the largest biotech hedge funds. Q1 2022 13F filings were made on or...
May 18, 2022
Jump start your biotech due diligence
Our platform helps you uncover your next biotech investment opportunity
bottom of page